Literature DB >> 30049630

N-terminal domain of Schmallenberg virus envelope protein Gc delivered by recombinant equine herpesvirus type 1 and modified vaccinia virus Ankara: Immunogenicity and protective efficacy in cattle.

Kerstin Wernike1, Alice Mundt2, Ellen Kathrin Link3, Andrea Aebischer4, Felicia Schlotthauer2, Gerd Sutter3, Robert Fux3, Martin Beer4.   

Abstract

Schmallenberg virus (SBV), which emerged in 2011 in Central Europe and subsequently spread very rapidly throughout the continent, affects predominantly ruminants. SBV is transmitted by insect vectors, and therefore vaccination is one of the major tools of disease control. Only recently, a domain connected to virus neutralization has been identified at the amino-terminal part of the viral envelope protein Gc. Here, this Gc domain delivered by recombinant EHV-1 or MVA vector viruses was tested in a vaccination-challenge trial in cattle, one of the major target species of SBV. The EHV-1-based vaccine conferred protection in two of four animals, whereas immunization using the MVA vector vaccine efficiently induced an SBV-specific antibody response and full protection against SBV challenge infection in all the vaccinated animals. Moreover, due to the absence of antibodies against SBVs N-protein, both vector vaccines enable the differentiation between vaccinated and field-infected animals making them to a promising tool to control SBV spread as well as to prevent disease in domestic ruminants.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Bunyavirales; Equine herpesvirus type 1; Marker diagnostics; Modified vaccinia virus Ankara; Vaccine; Viral vectors

Mesh:

Substances:

Year:  2018        PMID: 30049630     DOI: 10.1016/j.vaccine.2018.07.047

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  7 in total

1.  International proficiency trial demonstrates reliable Schmallenberg virus infection diagnosis in endemic and non-affected countries.

Authors:  Kerstin Wernike; Martin Beer
Journal:  PLoS One       Date:  2019-06-27       Impact factor: 3.240

Review 2.  Schmallenberg Disease-A Newly Emerged Culicoides-borne Viral Disease of Ruminants.

Authors:  Abaineh D Endalew; Bonto Faburay; William C Wilson; Juergen A Richt
Journal:  Viruses       Date:  2019-11-15       Impact factor: 5.048

3.  Immunogenicity and efficacy of Schmallenberg virus envelope glycoprotein subunit vaccines.

Authors:  Abaineh D Endalew; Bonto Faburay; Jessie D Trujillo; Natasha N Gaudreault; A Sally Davis; Vinay Shivanna; Sun Young Sunwoo; Wenjun Ma; Barbara S Drolet; D Scott McVey; Igor Morozov; William C Wilson; Juergen A Richt
Journal:  J Vet Sci       Date:  2019-11       Impact factor: 1.672

4.  A novel Schmallenberg virus subunit vaccine candidate protects IFNAR-/- mice against virulent SBV challenge.

Authors:  Hani Boshra; Gema Lorenzo; Diego Charro; Sandra Moreno; Gabriel Soares Guerra; Isbene Sanchez; Joseba M Garrido; Marivi Geijo; Alejandro Brun; Nicola G A Abrescia
Journal:  Sci Rep       Date:  2020-11-23       Impact factor: 4.379

5.  Differentiation of Antibodies against Selected Simbu Serogroup Viruses by a Glycoprotein Gc-Based Triplex ELISA.

Authors:  Kerstin Wernike; Andrea Aebischer; Franziska Sick; Kevin P Szillat; Martin Beer
Journal:  Vet Sci       Date:  2021-01-18

Review 6.  Vaccine development against Schmallenberg virus: from classical inactivated to modified-live to scaffold particle vaccines.

Authors:  Kerstin Wernike; Andrea Aebischer; Jean-Christophe Audonnet; Martin Beer
Journal:  One Health Outlook       Date:  2022-08-17

7.  Development of a Modular Vaccine Platform for Multimeric Antigen Display Using an Orthobunyavirus Model.

Authors:  Andrea Aebischer; Kerstin Wernike; Patricia König; Kati Franzke; Paul J Wichgers Schreur; Jeroen Kortekaas; Marika Vitikainen; Marilyn Wiebe; Markku Saloheimo; Ronen Tchelet; Jean-Christophe Audonnet; Martin Beer
Journal:  Vaccines (Basel)       Date:  2021-06-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.